MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)
Status:
Not yet recruiting
Trial end date:
2023-02-13
Target enrollment:
Participant gender:
Summary
This is a single-dose clinical study to evaluate the safety, tolerability, pharmacokinetics,
and anti-retroviral activity of MK-8527 in antiretroviral therapy (ART)-naïve participants
with human immunodeficiency virus type 1 (HIV-1) infection. The primary hypothesis is that,
at a dose that is safe and generally well tolerated, MK-8527 will have antiretroviral
activity as measured by a reduction from baseline in plasma HIV-1 ribonucleic acid (RNA) of
≥1.0 log10 copies/mL.